Back to top
more

Guardant Health (GH)

(Delayed Data from NSDQ)

$23.73 USD

23.73
2,645,936

-0.60 (-2.47%)

Updated Sep 6, 2024 04:00 PM ET

After-Market: $23.72 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?

Is (GH) Outperforming Other Medical Stocks This Year?

U.S. Consumer Spending Bolsters Economic Growth: 5 Picks

U.S. Consumer spending rises in November and with consumer sentiments' higher in December, these five stocks are a good buy.

Pacira's Exparel Spurs Growth, Exclusive Reliance a Concern

Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging. However, sole dependence on the drug is a constant worry.

ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study

ProQR (PRQR) doses the first patient in the phase I/II Aurora study on QR-1123, which is being evaluated for treating patients with autosomal dominant retinitis pigmentosa.

BioCryst Submits NDA for Hereditary Angioedema Candidate

BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.

VistaGen Up on Fast Track Designation for Anxiety Disorder Drug

The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.

Guardant Health, Gap, GameStop, Microsoft and Sony highlighted as Zacks Bull and Bear of the Day

Guardant Health, Gap, GameStop, Microsoft and Sony highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bull of the Day: Guardant Health (GH)

Cancer diagnostics provider just delivered 181% revenue growth and 18,500 tests to patients and labs

Top Ranked Momentum Stocks to Buy for December 6th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 6th

Spero Posts Preliminary Data on SPR720 for Pulmonary Disease

Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.

Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?

Is (GH) Outperforming Other Medical Stocks This Year?

Zacks.com featured highlights include: Kirkland Lake Gold, Target and Guardant Health

Zacks.com featured highlights include: Kirkland Lake Gold, Target and Guardant Health

Top Ranked Momentum Stocks to Buy for December 2nd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 2nd

Top 3 Momentum Anomaly Stocks to Buy for Healthy Profits

These stocks are currently witnessing short-term pullback in a bull market. So, this could just be the perfect entry point for investors who are looking to enhance their portfolio returns.

Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline

Alkermes (ALKS) will acquire Rodin Therapeutics for an upfront cash payment of $100 million and up to $850 million in milestone payments.

Guardant Health Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor Guardant Health.

Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?

Is (GH) Outperforming Other Medical Stocks This Year?

Top Ranked Momentum Stocks to Buy for November 12th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 12th

Guardant Health (GH) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Guardant Health (GH) closed at $70.96, marking a +0.45% move from the previous day.

Guardant Health (GH) to Report Q3 Earnings: What's in Store?

During Guardant Health's (GH) Q3 conference call, investors will watch out for the latest news on the colorectal cancer screening rates of its LUNAR-2 blood test.

Has Guardant Health (GH) Outpaced Other Medical Stocks This Year?

Is (GH) Outperforming Other Medical Stocks This Year?

Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?

Is (GH) Outperforming Other Medical Stocks This Year?

Exact Sciences Gets FDA Nod for Label Expansion of Cologuard

Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

Tirthankar Chakraborty headshot

3 Cancer Treatment Stocks to Enrich Your Portfolio

Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.